Outlook Therapeutics

About

Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics.

Cranbury,New Jersey,United States
101 - 250
https://outlooktherapeutics.com

Highlights

Details

Last Funding Type: Post-IPO Debt
Last Funding Money Raised: $6.80M
Industries: Biopharma,Biotechnology,Pharmaceutical,Therapeutics
Founded date: Jan 1, 2011
Number Of Employee: 101 - 250
Operating Status: Active
Stock Symbol: nasdaq:OTLK
Legal Name: Outlook Therapeutics, Inc.
Also Known As: Oncobiologics

Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development and technical excellence in order to create affordable medicines for patients around the world.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

12

$305.30M

Outlook Therapeutics has raised a total of $305.30M in funding over 2 rounds. Their latest funding was raised on Dec 23, 2022 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Dec 23, 2022	Post-IPO Equity	$25M	1	GMS Holdings	—	Detail
Dec 22, 2022	Post-IPO Debt	$6.80M	—	—	—	Detail
Nov 29, 2021	Post-IPO Equity	$57.50M	—	—	—	Detail
Feb 16, 2021	Post-IPO Equity	$42.60M	—	—	—	Detail
Jan 29, 2021	Post-IPO Equity	$35M	—	—	—	Detail

Investments

Number of Investments

Number of Lead Investments

1

0

Outlook Therapeutics has made 1 investments. Their most recent investment was on Aug 25, 2020, when Ocrolus raised $13.46M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Aug 25, 2020 Ocrolus	Series B	$13.46M	Banking	—

Investors

Number of Lead Investors

Number of Investors

6

9

Outlook Therapeutics is funded by 9 investors. GMS Holdings and Syntone Ventures are the most recent investors.

Investor Name	Lead Investor	Funding Round
GMS Holdings	Yes	Post-IPO Equity
Syntone Ventures	Yes	Post-IPO Equity
Biolexis	Yes	Post-IPO Equity
GMS Tenshi Holdings	Yes	Post-IPO Equity
Sabby Management	Yes	Series Unknown
Cormorant Global Healthcare Master Fund	—	Series Unknown
Longwood Capital Partners	—	Series Unknown
Perceptive Advisors	—	Series Unknown
venBio Partners	—	Series Unknown